Nitric oxide as a clinical guide for asthma management

Slides:

Advertisements

Similar presentations

Buffering airway acid decreases exhaled nitric oxide in asthma Benjamin Gaston, MD, Robin Kelly, RN, Peter Urban, RN, Lei Liu, PhD, Edward M. Henderson,

Advertisements

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial

Alveolar nitric oxide and asthma control in mild untreated asthma

What effect does asthma treatment have on airway remodeling

Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity Andrei Malinovschi,

Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery Albertien A.C. Aukema,

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Reduced exhaled nitric oxide values in children with asthma after inpatient rehabilitation at high altitude Johannes Huss-Marp, MD, Ursula Krämer, PhD,

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Differential effects of maintenance long-acting β-agonist and inhaled corticosteroid on asthma control and asthma exacerbations Peter G. Gibson, MBBS(Hons),

Alalia Berry, MD, William W. Busse, MD

Asthma diagnosis and treatment: Filling in the information gaps

The prevalence of severe refractory asthma

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Current application of exhaled nitric oxide in clinical practice

Is 9 more than 2 also in allergic airway inflammation?

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Airway hyperresponsiveness to mannitol and methacholine and exhaled nitric oxide: A random-sample population study Asger Sverrild, MD, Celeste Porsbjerg,

Stanley J. Szefler, MD, Richard J. Martin, MD

Keith J. Simons, PhD, Margherita Strolin Benedetti, PhD, F. Estelle R

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Treatment of chronic autoimmune urticaria with omalizumab

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma treatment and asthma prevention: A tale of 2 parallel pathways

Reply Journal of Allergy and Clinical Immunology

Jon Genuneit, MD, MSc Journal of Allergy and Clinical Immunology

Phillip Lieberman, MD, Michael Tankersley, MD

Blood eosinophils predict therapeutic effects of a GATA3-specific DNAzyme in asthma patients Norbert Krug, MD, Jens M. Hohlfeld, MD, Roland Buhl, MD,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Inhaled allergen bronchoprovocation tests

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Lisa G. Wood, PhD, Manohar L. Garg, PhD, Peter G. Gibson, MBBS

Effect of ingested H1 antihistamines on methacholine challenge

Airway hyperresponsiveness to mannitol and methacholine and exhaled nitric oxide: A random-sample population study Asger Sverrild, MD, Celeste Porsbjerg,

What is an “eosinophilic phenotype” of asthma?

Cephalosporin Side Chain Cross-reactivity

The widening black/white gap in asthma hospitalizations and mortality

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD,

Corinne A. Keet, MD, MS, Wayne G. Shreffler, MD, PhD, Roger D

Prevention of food allergy: Beyond peanut

E. Rand Sutherland, MD, MPH Journal of Allergy and Clinical Immunology

Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children Georgette Stern, MSc, Johan de Jongste, MD, Ralf.

Lars Pedersen, MD, PhD, Thomas K

Endotoxin and the lung: Insight into the host-environment interaction

Measles and immunomodulation

The Editors' Choice Journal of Allergy and Clinical Immunology

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

The Editors' Choice Journal of Allergy and Clinical Immunology

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

Perception of risk associated with asthma research procedures among adolescents, parents, and pediatricians Robert D. Annett, PhD, Janet L. Brody, PhD,

Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol

Valérie Bougault, PhD, Julie Turmel, MSc, Louis-Philippe Boulet, MD

Advances in pediatric asthma in 2007

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

The influence of asthma control on the severity of virus-induced asthma exacerbations David J. Jackson, MRCP, PhD, Maria-Belen Trujillo-Torralbo, BSc,

Primary prevention of asthma and allergy

Presentation transcript:

Nitric oxide as a clinical guide for asthma management D. Robin Taylor, MD, FRCPC Journal of Allergy and Clinical Immunology Volume 117, Issue 2, Pages 259-262 (February 2006) DOI: 10.1016/j.jaci.2005.11.010 Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 1 Changes in FEV1 (% improvement) following 4 weeks of treatment with inhaled fluticasone 500 μg/d in 52 subjects with chronic nonspecific respiratory symptoms, stratified by baseline FENO (tertiles). The changes in FEV1 were significantly higher in the group with the highest FENO (greater than 47 ppb) using 1-way ANOVA for trends across all 3 groups (P < .01). Data are also given after stratifying by clinical diagnosis made at the time of initial presentation based on symptoms, bronchodilator response, and/or a positive test for airway hyperresponsiveness (asthma versus nonasthma).7 Journal of Allergy and Clinical Immunology 2006 117, 259-262DOI: (10.1016/j.jaci.2005.11.010) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 2 Distribution of mean inhaled fluticasone doses (over 12 months) in 2 asthma management groups, one using FENO measurements (n = 46) and the other conventional group in which symptoms, bronchodilator use, and lung function were used in accordance with a priori criteria (n = 48). There was a highly significant difference between the 2 groups (P = .008). Downward dose adjustments were made in the FENO group if the FENO level was less than 35 ppb.14 Journal of Allergy and Clinical Immunology 2006 117, 259-262DOI: (10.1016/j.jaci.2005.11.010) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions